Biotechnology company developing treatments for rare genetic diseases of the central nervous system. Its lead product, leriglitazone, is a brain-penetrant selective PPAR-gamma agonist developed for X-linked adrenoleukodystrophy, with additional clinical programs in Rett syndrome and Friedreich’s ataxia. In September 2026 the European Commission authorised NEZGLYAL (leriglitazone) under exceptional circumstances for a defined group of boys aged 2–12 with cerebral adrenoleukodystrophy and non-enhancing brain lesions; other indications remain in development. Minoryx conducts drug discovery, translational research and clinical development from Mataró, Spain, and Gosselies, Belgium, and works with Neuraxpharm on European commercialisation and continued development.
